All questionsIndication: Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer4 questions · 2 sourcesIndicationWhat is KEYTRUDA (pembrolizumab) approved for in early-stage triple-negative breast cancer?“KEYTRUDA and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection 165 mg + 2,000 units/mL are each indicated for the treatment of adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then each continued as a single agent as adjuvant treatment after surgery.” (opens the source at this quote in a new tab)CopyFlagCan KEYTRUDA QLEX (subcutaneous pembrolizumab) be used instead of IV KEYTRUDA for early-stage TNBC?“The effectiveness of KEYTRUDA QLEX for its approved indications has been established based upon evidence from the adequate and well-controlled studies conducted with KEYTRUDA and additional data comparing the pharmacokinetic, efficacy, and safety profiles of KEYTRUDA QLEX and KEYTRUDA.” (opens the source at this quote in a new tab)CopyFlag“Pembrolizumab and berahyaluronidase alfa-pmph subcutaneous injection may be substituted for IV pembrolizumab. Pembrolizumab and berahyaluronidase alfa-pmph (KEYTRUDA QLEX) has different dosing and administration instructions compared to IV pembrolizumab (KEYTRUDA)” (opens the source at this quote in a new tab)CopyFlagDrug namesWhat is the generic name of KEYTRUDA?“KEYTRUDA® (pembrolizumab) injection, for intravenous use” (opens the source at this quote in a new tab)CopyFlagTestingDoes PD-L1 expression affect KEYTRUDA eligibility in early-stage TNBC?“Patients May be Eligible for a Regimen Including KEYTRUDA or KEYTRUDA QLEX Regardless of Tumor PD-L1 Expression” (opens the source at this quote in a new tab)CopyFlag“Patients were enrolled regardless of tumor PD-L1 expression” (opens the source at this quote in a new tab)CopyFlagNote: The first passage heads a hypothetical patient profile based on patients studied in KEYNOTE-522; the second is a KEYNOTE-522 inclusion criterion.